retatrutide kidney and Chronic Disease: What the 2026 Meta-Analysis Adds | PeptIQ Blog Retatrutide: A Triple Agonist Shaping

The authors were unsure how well obese was recording in patients in the cohort

Some research has demonstrated systemic anti-inflammatory and neuroprotective benefits in patients with diabetes, but specific data regarding risk for age-related macular degeneration (AMD) in those without the disease is minimal

doi: 10.2337/DIABETES.51.2007.S434 61 DahlKBrooksAAlmazediFHoffSTBoschiniCBkdalTA

A recently proposed federal rule may require Medicaid and Medicare to cover GLP-1s when used to treat obesity

Researchers at the Scandinavian Journal of Primary Health Care in 2025 found that GLP-1 users felt fuller and satisfied after their meals and that they had an easier time managing cravings